Caregivers should watch for nausea, vomiting, diarrhea, appetite loss, weight loss, worsening tremor, fainting, slowed heart rate, and concerning skin reactions. They should also confirm that only one rivastigmine patch is worn and contact the prescriber before restarting after an interruption longer than three days. A rivastigmine patch delivers medicine through the skin. It may ease symptoms of Alzheimer's dementia or mild-to-moderate Parkinson's disease dementia, but it does not cure the underlying dementia.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which side effects are most common?
- How should caregivers track appetite and weight?
- When is a patch-site reaction concerning?
- How can patch and restart errors be prevented?
- Who may need closer monitoring?
Which side effects are most common?
Stomach and intestinal problems deserve close attention because they can worsen as the dose increases. The FDA label specifically identifies nausea, vomiting, diarrhea, appetite loss, and weight loss as concerns. In a trial of 1,195 patients, the 9.5-mg/24-hour patch caused nausea in 7%, vomiting in 6%, and diarrhea in 6%.
The corresponding placebo rates were 5%, 3%, and 3%, according to the FDA prescribing information revised in May 2024. These percentages show that many patients did not report these effects, but caregivers still need to notice persistent symptoms. Prolonged vomiting or diarrhea can cause dehydration and serious outcomes.
How should caregivers track appetite and weight?
Record appetite changes, vomiting, diarrhea, and weight in one place. A short log can help the prescriber see whether symptoms began after treatment started or after a dose increase. In the same trial, 8% of patients using the 9.5-mg/24-hour patch lost at least 7% of their starting weight, compared with 6% using placebo.
The FDA label notes that the role of gastrointestinal symptoms was unclear. Report ongoing appetite loss or measurable weight loss rather than waiting for the next routine visit. For perspective, a 7% loss equals 10.5 pounds for someone who started at 150 pounds.
When is a patch-site reaction concerning?
Watch the skin after removing each patch. Redness, swelling, small raised bumps called papules, or blisters may indicate allergic contact dermatitis if the reaction becomes more intense or spreads beyond the patch area. A reaction is also concerning if it does not improve within 48 hours after patch removal.
Under those circumstances, contact the prescriber promptly; the FDA label says treatment should be discontinued. Do not judge the reaction only by its appearance at one moment. Note whether it is spreading, worsening, or still present two days after removal so the prescriber receives specific information.
How can patch and restart errors be prevented?
Applying a new patch without removing the previous one can cause an overdose. Reported errors have led to serious reactions, hospitalization, and, rarely, death, so the FDA directs caregivers to ensure that only one patch is worn.
Use a simple routine for every change: If treatment stops for more than three days, do not simply resume the previous dose. Contact the prescriber first; the FDA label directs restarting at 4.6 mg/24 hours to reduce the risk of severe vomiting.
- Find and remove the old patch before opening a new one.
- Confirm visually that only one patch remains on the person.
- Record the date and time of the change.
- Tell other caregivers when the patch has been replaced.
Who may need closer monitoring?
People with ulcers or those taking nonsteroidal anti-inflammatory drugs, commonly called NSAIDs, warrant monitoring for gastrointestinal bleeding. People with sick-sinus syndrome or other heart-conduction problems may be especially vulnerable to a slowed heart rate.
Beta-blockers can add to the risk of slowed heart rate and fainting. Rivastigmine can also worsen tremor or other parkinsonian symptoms. Give the prescriber a complete medication list, including NSAIDs and beta-blockers, and report fainting, worsening tremor, or concern about gastrointestinal bleeding.
